Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245535 | 0.93 | PIK3CA (0.54) | PIK3CAPIK3CDRAF1BRAFMTOR | |
| SCHEMBL249034 | 0.92 | PIK3CA (0.45) | PIK3CAPIK3CDRAF1BRAFKIT | |
| SCHEMBL248117 | 0.86 | PIK3CA (0.51) | PIK3CAPIK3CDMTORTDO2 | |
| SCHEMBL248782 | 0.85 | PIK3CA (0.49) | PIK3CAPIK3CDTGFBR1TDO2 | |
| SCHEMBL247290 | 0.85 | PIK3CA (0.52) | PIK3CAPIK3CDKITMAPTIRAK4 | |
| SCHEMBL2712876 | 0.83 | PIK3CA (0.59) | PIK3CAPIK3CD | |
| SCHEMBL2711544 | 0.83 | PIK3CA (0.64) | PIK3CAPIK3CD | |
| SCHEMBL248754 | 0.80 | PIK3CA (0.47) | PIK3CAPIK3CDBRAFKITMTOR | |
| SCHEMBL2729435 | 0.79 | PIK3CA (0.60) | PIK3CAPIK3CD | |
| SCHEMBL248486 | 0.78 | PIK3CA (0.53) | PIK3CAPIK3CDRAF1BRAFMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885PIK3CD 24/4885RAF1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.